Search

Displaying results 2111 - 2120 of 5898 in total
  1. Drug

    GTS-21

    go.drugbank.com/drugs/DB05708
    Investigational

    GTS-21 has been studied in multiple Phase I studies in healthy volunteers and one Phase I/II study in schizophrenic patients. In all studies, the compound was well tolerated. … Athenagen licensed the exclusive rights to the compound and a related library of analogs as part of the acquisition of Osprey Pharmaceutical Company in April 2006.

  2. Drug

    Loxoprofen

    go.drugbank.com/drugs/DB09212
    ApprovedInvestigational

    Loxoprofen is a propionic acid derivative non-steroidal anti-inflammatory drug. It is marketed under the trade name Loxonin in Brazil, Mexico and Japan by Sankyo, as Loxomac in India, and as Oxeno in Argentina. A transdermal preparation ...

  3. Drug

    Lenograstim

    go.drugbank.com/drugs/DB13144
    ApprovedWithdrawn

    Lenograstim is a recombinant granulocyte colony-stimulating factor used as an immunostimulating agent.

  4. Drug

    Thymalfasin

    go.drugbank.com/drugs/DB04900
    Investigational

    It is also used to boost the immune response in the treatment of other diseases. … Thymalfasin is a chemically synthesized version of thymosin alpha 1 that is identical to human thymosin alpha 1. Thymosin alpha 1 is an acetylated polypeptide.

  5. Drug

    Reviparin

    go.drugbank.com/drugs/DB09259
    Approved

    Reviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin.

  6. Drug

    Ritodrine

    go.drugbank.com/drugs/DB00867
    ApprovedWithdrawn

    Adrenergic beta-agonist used to control premature labor.

  7. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.

  8. Drug

    Bezafibrate

    go.drugbank.com/drugs/DB01393
    ApprovedInvestigational

    Antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.

  9. Target

    Volume-regulated anion channel subunit LRRC8A

    go.drugbank.com/bio_entities/BE0016599
    TargetHumans

    Essential component of the volume-regulated anion channel (VRAC, also named VSOAC channel), an anion channel required to maintain a constant cell volume in response to extracellular or intracellular osmotic changes (PubMed:24725410, PubM...

    Synonyms: Leucine-rich repeat-containing protein 8A
  10. Drug

    Nabiximols

    go.drugbank.com/drugs/DB14011
    Investigational

    adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy. … In contrast to THC's weak agonist activity, CBD has been shown to act as a negative allosteric modulator of the cannabinoid CB1 receptor, the most abundant G-Protein Coupled Receptor (GPCR) in the body